What OncoMed's Deal With Celgene Means for Investors

Before you go, we thought you'd like these...
Before you go close icon

Investors may have missed OncoMed Pharmaceuticals in the flurry of biotech IPOs this year, but last week's pop was more than enough to raise a few eyebrows. Shares soared more than 80% after the company announced a deal with big biotech Celgene . In the following video, analysts Simon Erickson and Max Macaluso discuss the details of the deal, what it means for both OncoMed and Celgene, and whether partnerships like this will be a continuing trend in the biotech space.

Growth stock to watch now
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

The article What OncoMed's Deal With Celgene Means for Investors originally appeared on Fool.com.

Max Macaluso, Ph.D. owns shares of Celgene. Simon Erickson has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading